Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for C5A5R0

Entry ID Method Resolution Chain Position Source
AF-C5A5R0-F1 Predicted AlphaFoldDB

No variants for C5A5R0

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for C5A5R0

No associated diseases with C5A5R0

2 regional properties for C5A5R0

Type Name Position InterPro Accession
domain Fibrinogen, alpha/beta/gamma chain, C-terminal globular domain 141 - 383 IPR002181
conserved_site Fibrinogen, conserved site 333 - 345 IPR020837

Functions

Description
EC Number 6.1.1.1 Ligases forming aminoacyl-tRNA and related compounds
Subcellular Localization
  • Cytoplasm
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.

2 GO annotations of molecular function

Name Definition
ATP binding Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
tyrosine-tRNA ligase activity Catalysis of the reaction: L-tyrosine + ATP + tRNA(Tyr) = L-tyrosyl-tRNA(Tyr) + AMP + diphosphate + 2 H(+).

1 GO annotations of biological process

Name Definition
tyrosyl-tRNA aminoacylation The process of coupling tyrosine to tyrosyl-tRNA, catalyzed by tyrosyl-tRNA synthetase. The tyrosyl-tRNA synthetase is a class-I synthetase. The activated amino acid is transferred to the 2'-OH group of a tyrosine-accetping tRNA. The 2'-O-aminoacyl-tRNA will ultimately migrate to the 3' position via transesterification.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MDVEKKIELI KKKPTEELLT EENLRHLFEV GIPMQHYIGF EISGYIHLGT GLMAGAKIAD
70 80 90 100 110 120
LQKAGIKTRI FLADWHSWIN DKLGGDLETI QKVALTYFKE GMKQSIKVMG GDPDKVEFVL
130 140 150 160 170 180
ASEILEKGDY WQTVIDISKN VTLARMMRSI TIMGRQMGES IDFAKLIYPA MQVADIFYQG
190 200 210 220 230 240
VTIAHAGMDQ RKAHVIAIEV AQKLKYHPLE WKGEKLKPVA LHHHLLLGLQ EPPVWPIESE
250 260 270 280 290 300
EQFKELKTQM KMSKSKPYSA VFIHDSPEEI RQKLRKAFCP AREVRYNPVL DWAEYIIFRE
310 320 330 340 350 360
EPTEFTIHRP AKFGGDVTYT TSEELKRDFA EGKLHPLDLK NAVAEYLIEL LKPVREYFEK
370
HPEPLELMRE VKITR